研究紹介

発表論文(国際)

2021-01.

Iida K, Miyake M, Murakami K, Komiyama M, Okajima E, Sazuka T, Nishiyama N, Yasumoto H, Kimura T, Ito A, Shiga K, Yamagishi A, Kikuchi H, Sugimoto M, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K: Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy. Int J Clin Oncol. 2021 Nov; 26 (11): 2104-2112. [5y-IF: 3.467]

2021-02.

Iwami D, Matsumoto T, Ono K, Hotta K, Ota M, Chiba Y, Sasaki H, Hirose T, Higuchi H, Takada Y, Iwahara N, Murai S, Shinohara N: Novel double-filtration plasmapheresis preserves fibrinogen while removing immunoglobulin-G antibodies before ABO blood type-incompatible kidney transplantation. Renal Replacement Therapy. 2021 7 (1): doi: https://doi.org/10.1186/s41100-021-00379-z. [5y-IF: N/A]

2021-03.

Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H, Japan Urological Oncology Group: Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. Int J Urol. 2021 Dec; 28 (12): 1261-1267. [5y-IF: 3.011]

2021-04.

Kobayashi S, Sata F, Ikeda-Araki A, Miyashita C, Itoh S, Goudarzi H, Iwasaki Y, Mitsui T, Moriya K, Shinohara N, Cho K, Kishi R: Associations among maternal perfluoroalkyl substance levels, fetal sex-hormone enzymatic gene polymorphisms, and fetal sex hormone levels in the Hokkaido study. Reprod Toxicol. 2021 Oct; 105: 221-231. [5y-IF: 3.98]

2021-05.

Kon M, Nakamura M, Moriya K, Nishimura Y, Hirata Y, Nishida M, Higuchi M, Kitta T, Shinohara N: What are the Optimal Renal Ultrasound Parameters for Detecting Small Kidney in Young Children? Res Rep Urol. 2021 Oct; 13: 767-772. [5y-IF: N/A]

2021-06.

Konno M, Osawa T, Hotta K, Shimizu A, Abe T, Matsumoto R, Kikuchi H, Shinohara N: Primary renal leiomyosarcoma with a tumor thrombus in the inferior vena cava. IJU Case Rep. 2021 Nov; 5 (1): 66-69. [5y-IF: N/A]

2021-07.

Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K, Yakabe T, Yoshimura T, Takao S, Shinohara N, Aoyama H, Shimizu S, Shirato H: Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy? BJR Open. 2021 Nov; 3 (1): 20210064. [5y-IF: N/A]

2021-08.

Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M, Japanese Urological Oncology Group: Novel metastatic burden- stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Cancer Sci. 2021 Sep; 112 (9): 3616-3626. [5y-IF: 6.622]

2021-09.

Shoji T, Niida Y, Osawa T, Matsumoto R, Sakurai K, Suzuki M, Matsuno Y, Konno S: Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex. Respir Med Case Rep. 2021 Oct; 34: 101526. [5y-IF: N/A]

2021-10.

Takeda H, Matsumoto R, Takakuwa E, Hori K, Moriguchi T, Yamada S, Kikuchi H, Osawa T, Abe T, Shinohara N: Favorable response to pembrolizumab in granulocyte colony-stimulating factor-producing upper urinary tract urothelial carcinoma. IJU Case Rep. 2021 Dec; 5 (2): 108-112. [5y-IF: N/A]

2021-11.

Uemura M, Nakaigawa N, Sassa N, Tatsugami K, Harada K, Yamasaki T, Matsubara N, Yoshimoto T, Nakagawa Y, Fukuyama T, Oya M, Shinohara N, Uemura H, Tsuzuki T: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma. Int J Clin Oncol. 2021 Nov; 26 (11): 2073-2084. [5y-IF: 3.467]

2021-12.

Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Yamada S, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa O, Shinohara N, Suzukamo Y, Ito A, Arai Y: Health-Related Quality of Life in Testicular Cancer Survivors in Japan: A Multi-Institutional, Cross-Sectional Study Using the EORTC QLQ-TC26. Urology. 2021 Oct; 156: 173-180. [5y-IF: 2.548]

2021-13.

Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Yamada S, Nishimura K, Nonomura N, Kojo K, Shiraishi T, Ukimura O, Ogawa O, Shinohara N, Suzukamo Y, Ito A, Arai Y: Fertility and reproductive technology use in testicular cancer survivors in Japan: A multi-institutional, cross-sectional study. Int J Urol. 2021 Oct; 28 (10): 1047-1052. [5y-IF: 3.011]

2022-01.

Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Shinohara N: Examination of pelvic floor muscle elasticity in patients with interstitial cystitis/bladder pain syndrome using real-time tissue elastography. Int Urogynecol J. 2022 Mar; 33 (3): 619-626. [5y-IF: 2.426]

2022-02.

Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Shinohara N: Evaluation of pelvic floor muscle elasticity in patients with overactive bladder syndrome using real-time tissue elastography. Eur J Obstet Gynecol Reprod Biol. 2022 Sep; 276: 9-13. [5y-IF: 2.778]

2022-03.

Aydın A, Ahmed K, Abe T, Raison N, V an Hemelrijck M, Garmo H, Ahmed HU, Mukhtar F, Al-Jabir A, Brunckhorst O, Shinohara N, Zhu W, Zeng G, Sfakianos JP, Gupta M, Tewari A, Gözen AS, Rassweiler J, Skolarikos A, Kunit T, Knoll T, Moltzahn F, Thalmann GN, Lantz Powers AG, Chew BH, Sarica K, Shamim Khan M, Dasgupta P SIMULATE Trial Group: Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial. Eur Urol. 2022 Apr; 81 (4): 385-393. [5y-IF: 21.729]

2022-04.

Chiba H, Kitta T, Higuchi M, Kusakabe N, Kon M, Nakamura M, Shinohara N: Ureteral reimplantation during augmentation cystoplasty is not needed for vesicoureteral reflux in patients with neurogenic bladder: a long-term retrospective study. BMC Urol. 2022 Mar; 22 (1): 48. [5y-IF: 2.317]

2022-05.

Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N: Objective evaluation of laparoscopic surgical skills in wet lab training based on motion analysis and machine learning. Langenbecks Arch Surg. 2022 Aug; 407 (5): 2123-2132. [5y-IF: 3.116]

2022-06.

Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Tozawa A, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Osuga Y, Suzuki N: Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. Int J Clin Oncol. 2022 Feb; 27 (2): 265-280. [5y-IF: 3.467]

2022-07.

Hayashi A, Yamamoto I, Kawabe M, Kobayashi A, Ito M, Hotta K, Shinohara N, Tasaki T, Yokoo T, Iwami D: CASE REPORT: Serial Cases of False-Positive Flow- Cytometry T Cell Crossmatch Associated With Anti-Blood Type Antibodies in Patients Undergoing ABO-Incompatible Kidney Transplantation. Front Immunol. 2022 Mar; 13: 862652. [5y-IF: 8.876]

2022-08.

Hayashi A, Okamoto T, Nio-Kobayashi J, Iwahara N, Suzuki R, Ueda Y, Takahashi T, Yasuyuki S, Iwanaga T, Hotta K: CD44 as a pathological marker for the early detection of calcineurin inhibitor-induced nephrotoxicity post kidney transplantation. Biomed Res(Tokyo). 2022 43 (5): 181-186. [5y-IF: 4.308]

2022-09.

Hirata Y, Higuchi M, Osawa T, Hinotsu S, Harabayashi T, Mochizuki T, Enami N, Nounaka O, Shinno Y, Kikuchi H, Matsumoto R, Abe T, Murai S, Shinohara N: Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods. Int J Urol. 2022 Oct; 29 (10): 1140-1146. [5y-IF: 3.011]

2022-10.

Hirose T, Ma D, Lassiter G, Sasaki H, Rosales I, Coe TM, Rickert CG, Matheson R, Colvin RB, Qin W, Kan Y , Layer JV , Paragas VB, Stiede K, Hall KC, Y oud ME, Queiroz LM, Westlin WF, Curtis M, Y ang L, Markmann JF, Kawai T: Kidney transplantation from triple-knockout pigs expressing multiple human proteins in cynomolgus macaques. American Journal of Transplantation. 2022 22 (1): 46-57. [5y-IF: 8.039]

2022-11.

Hirose T, Hotta K, Harada H, Tanabe T, Sasaki H, Shinohara N: Vesicoureteral reflux treatment following kidney transplantation potentially prevents graft function deterioration and allows long-term graft survival. Int J Urol. 2022 Jul; 29 (7): 699-706. [5y-IF: 3.011]

2022-12.

Hirose T, Hotta K, Shinohara N: Response to Re: Vesicoureteral reflux treatment following kidney transplantation potentially prevents graft function deterioration and allows long-term graft survival. Int J Urol. 2022 Oct; 29 (10): 1245-1246. [5y-IF: 3.011]

2022-13.

Hotta K, Hirose T, Kawai T: Clinical trials for renal allograft tolerance induction through combined hematopoietic stem cell transplantation: A narrative review. Int J Urol. 2022 Sep 13; doi: 10.1111/iju.15035. [5y-IF: 3.011]

2022-14.

Kato T, Yokomizo A, Matsumoto R, Tohi Y, Miyakawa J, Mitsuzuka K, Sasaki H, Inokuchi J, Matsumura M, Sakamoto S, Kinoshita H, Fukuhara H, Kamiya N, Kimura R, Nitta M, Okuno H, Akakura K, Kakehi Y, Sugimoto M: Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study. Int J Urol. 2022 Jul; doi: 10.1111/iju.14977. [5y-IF: 3.011]

2022-15.

Kawahara T, Kawai K, Kojima T, Nagumo Y, Sakka S, Kandori S, Negoro H, Mathis BJ, Maruo K, Miura K, Sakamoto N, Shinohara N, Yamashita S, Yonemori K, Kishida T, Ukimura O, Nishimura K, Kobayashi Y, Nishiyama H: Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors. Int J Urol. 2022 Jul; 29 (7): 741-747. [5y-IF: 3.011]

2022-16.

Kikuchi H, Osawa T, Matsumoto R, Abe T, Maruyama S, Harabayashi T, Miyata H, Kashiwagi A, Ikeshiro S, Sazawa A, Fukui R, Morita K, Takeuchi I, Hori K, Yamashita N, Minami K, Mochizuki T, Murai S, Shinohara N: Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma. Urol Oncol. 2022 Jan; 40 (1): 13.e19-13.e27. [5y-IF: 3.011]

2022-17.

Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, Shinohara N: Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era. Int J Urol. 2022 Mar; 29 (3): 251-258. [5y-IF: 3.011]

2022-18.

Kita Y, Ito K, Kanda S, Joraku A, Yamaguchi R, Shimizu Y, Hayata N, Somiya S, Shibasaki N, Kimura T, Hikami K, Yamada T, Abe T, Tsuchihashi K, Tatarano S, Nishiyama H, Kitamura H, Kobayashi T: Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction. Urol Oncol. 2022 Sep; 40 (9): 410.e11-410.e18. [5y-IF: 3.099]

2022-19.

Kitta T, Abe H, Ting-Wen H, Fujikawa M, Nakazono M, Sasa T, Doi Y, Toki S, Okada D, Ochi A, Suzuki K, Kitagawa Y, Shinohara N: Novel insight into the correlation between hernia orifice of cystocele and lower urinary tract function: a pilot study. BMC Womens Health. 2022 May; 22 (1): 164. [5y-IF: 3.256]

2022-20.

Kitta T, Chiba H, Kon M, Higuchi M, Kusakabe N, Ouchi M, Togo M, Abe-Takahashi Y, Tsukiyama M, Shinohara N: Urodynamic evaluation of the efficacy ofvibegron, a new β3-adrenergic receptor agonist, on lower urinary tract functionin children and adolescents with overactive bladder. J Pediatr Urol. 2022 Jul; S1477-5131(22)00316-3. [5y-IF: 2.102]

2022-21.

Kobayashi K, Matsuyama H, Kawai T, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Komura K, Abe T, Kume H, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Inoue K, Mitsui T, Kawakita M, Ohyama C, Mizokami A, Kuroiwa H: Bladder cancer prospective cohort study on high-risk non-muscle invasive bladder cancer after photodynamic diagnosis-assisted transurethral resection of the bladder tumor (BRIGHT study). Int J Urol. 2022 Jul; 29 (7): 632-638. [5y-IF: 3.011]

2022-22.

Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y,Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, Shinohara N: Automatic assessment of laparoscopic surgical skill competence based on motion metrics. PLoS One. 2022 Nov; 17 (11): e0277105. [5y-IF: 4.069]

2022-23.

Kusakabe N, Kitta T, Chiba H, Higuchi M, Shinohara N: A case of pubic osteomyelitis after implantation of an artificial urinary sphincter: A case report. Low Urin Tract Symptoms. 2022 Jan; 14 (1): 78-81. [5y-IF: N/A]

2022-24.

Maishi N, Sakurai Y, Hatakeyama H, Umeyama Y, Nakamura T, Endo R, Alam MT, Li C, Annan DA, Kikuchi H, Morimoto H, Morimoto M, Akiyama K, Ohga N, Hida Y, Harashima H, Hida K: Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system. Cancer Sci. 2022 May; 113 (5): 1855-1867. [5y-IF: 6.622]

2022-25.

Miura M, Fukumoto M, Komatsu N, Shuto R, Harada H, Sasaki H: Temporary reduction of immunosuppression enhances production of anti-S antibody against severe acute respiratory syndrome coronavirus 2 after vaccination in kidney transplant recipients. Int J Urol. 2022 Sep; doi: 10.1111/iju.15027. [5y-IF: 3.011]

2022-26.

Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T: GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy. Cancer Immunol Immunother. 2022 Apr; 71 (4): 795-806. [5y-IF: 6.693]

2022-27.

Murakami Y, Matsumoto K, Miyake M, Amano N, Shimura S, Nishimura N, Iida K, Matsushita Y, Abe T, Yamada T, Uemura M, Matsui Y, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K: Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Int J Urol. 2022 Jul 20; doi: 10.1111/iju.14976. [5y-IF: 3.011]

2022-28.

Nakajima N, Miyajima A, Shinohara N, Obara W, Kondo T, Kimura G, Kume H, Fujimoto H, Sugiyama T, Nonomura N, Hongo F, Fukumori T, Takahashi M, Kanayama HO, Eto M: Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Jpn J Clin Oncol. 2022 Mar; 52 (3): 274-280. [5y-IF: 2.864]

2022-29.

Narita H, Takenaka J, Watanabe S, Abe T, Kudo K: Retroperitoneal Chronic Expanding Hematoma Mimicking Malignancy on FDG PET/CT. Clin Nucl Med. 2022 Sep; 47 (9): e591-e593. [5y-IF: 7.77]

2022-30.

Nishimura Y, Moriya K, Kobayashi S, Ikeda-Araki A, Sata F, Mitsui T, Itoh S, Miyashita C, Cho K, Kon M, Nakamura M, Kitta T, Murai S, Kishi R, Shinohara N: Association of exposure to prenatal perfluoroalkyl substances and estrogen receptor 1 polymorphisms with the second to fourth digit ratio in school-aged children: The Hokkaido study. Reprod Toxicol. 2022 Apr; 109: 10-18. [5y-IF: 3.98]

2022-31.

Numakura K, Nakai Y, Kojima T, Osawa T, Narita S, Nakayama M, Kitamura H, Nishiyama H, Shinohara N: Overview of clinical management for older patients with renal cell carcinoma. Jpn J Clin Oncol. 2022 Jul; 52 (7): 657-673. [5y-IF: 2.864]

2022-32.

Oishi Y, Kitta T, Osawa T, Abe T, Shinohara N, Nosato H, Sakanashi H, Murakawa M: Diagnosis and Localization of Prostate Cancer via Automated Multiparametric MRI Equipped with Artificial Intelligence. Uro. 2022; 2 (1): 21-29. [5y-IF: N/A]

2022-33.

Osawa T, Abe T, Kikuchi H, Matsumoto R, Murai S, Nakao T, Tanaka S, Watanabe A, Shinohara N: Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms. PLoS One. 2022 Mar; 17 (3): e0265230. [5y-IF: 4.069]

2022-34.

Ouchi M, Kitta T, Chiba H, Higuchi M, Togo M, Abe-Takahashi Y, Shinohara N: Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson's disease. Sci Rep. 2022 Mar; 12 (1): 4540. [5y-IF: 5.516]

2022-35.

Rosales I, Mahowald G, Tomaszewski K, Hotta K, Iwahara N, Otsuka T, Tsuji T, Takada Y, Acheampong E, Araujo-Medina M, Bruce A, Rios A, Cosimi AB, Elias N, Kawai T, Gilligan H, Safa K, Riella L, Tolkoff-Runim N, Williams W, Colvin R: Banff Human Organ Transplant Transcripts Correlate with Renal Allograft Pathology and Outcome: Importance of Capillaritis and Subpathologic Rejection. Journal of american society of nephrology. 2022 Sep; doi: https://doi.org/10.1681/ASN.2022040444. [5y-IF: 12.796]

2022-36.

Shiota M, Takamatsu D, Kimura T, Tashiro K, Matsui Y, Tomida R, Saito R, Tsutsumi M, Yokomizo A, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Narita S, Matsumoto R, Kasahara T, Hashimoto K, Matsumoto H, Kato M, Akamatsu S, Joraku A, Kato M, Yamaguchi T, Saito T, Kaneko T, Takahashi A, Kato T, Sakamoto S, Enokida H, Kanno H, Terada N, Suekane S, Nishiyama N, Eto M, Kitamura H, Japanese Urological Oncology Group: Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node- positive prostate cancer. Cancer Sci. 2022 Jul; 113 (7): 2386-2396. [5y-IF: 6.622]

2022-37.

Sugimoto M, Kato T, Tohi Y, Shimizu Y, Matsumoto R, Inoue T, Takezawa Y, Masui K, Sasaki H, Hirama H, Saito S, Egawa S, Kamoto T, Teramukai S, Kojima S, Kikuchi T, Kakehi Y: Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)-a prospective single-arm interventional study. BMC Urol. 2022 Sep; 22 (1): 151. [5y-IF: 2.317]

2022-38.

Suzuki M, Miyaji K, Watanabe R, Suzuki T, Matoba K, Nakazono A, Nakamaru Y, Konno A, Psaltis AJ, Abe T, Homma A, Wormald PJ: Repetitive simulation training with novel 3D-printed sinus models for functional endoscopic sinus surgeries. Laryngoscope Investig Otolaryngol. 2022 Jul; 7 (4): 943-954. [5y-IF: 2.857]

2022-39.

Takamoto D, Sasaki H, Kataoka H, Kodama F, Higuchi H, Hirano T, Takada Y, Harada S, Harada H, Tanaka H: Successful immunomodulation in kidney transplant recipients with cytokine release syndrome after coronavirus disease. IJU Case Rep. 2022 Jun; 5 (5): 373-377. [5y-IF: N/A]

2022-40.

Takayanagi A, Kato F, Nozaki A, Matsumoto R, Osawa T, Kuwahara K, Matsuno Y, Asano H, Kato T, Watari H, Abe T, Shinohara N, Kudo K: Imaging findings of ovarian metastasis of primary renal cell carcinoma: A case report and literature review. Radiol Case Rep. 2022 May; 17 (7): 2320-2327. [5y-IF: N/A]

2022-41.

Tasaki M, Tateno H, Sato T, Tomioka A, Kaji H, Narimatsu H, Saito K, Nakagawa Y, Aoki T, Kamimura M, Ushiki T, Okada M, Miwa Y, Hotta K, Yoshida Y, Takahashi K, Tomita Y: A Novel Method of CD31-Combined ABO Carbohydrate Antigen Microarray Predicts Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation. Transpl Int. 2022 Mar; 35: 10248. [5y-IF: 4.008]

2022-42.

Tohi Y, Kato T, Yokomizo A, Mitsuzuka K, Tomida R, Inokuchi J, Matsumoto R, Saito T, Sasaki H, Inoue K, Kinoshita H, Fukuhara H, Maruyama S, Sakamoto S, Tanikawa T, Egawa S, Ichikura H, Abe T, Nakamura M, Kakehi Y, Sugimoto M: Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN study. Urol Oncol. 2022 Feb; 40 (2): 56.e9-56.e15. [5y-IF: 3.099]

2022-43.

Tohi Y, Kato T, Nakamura M, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Hashine K, Yokomizo A, Naito H, Hara I, Kawamura N, Inoue M, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Egawa S, Kakehi Y, Sugimoto M: Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study. Int J Clin Oncol. 2022 Jan; 27 (1): 194-201. [5y-IF: 3.467]

2022-44.

Tohi Y, Kato T, Miyakawa J, Matsumoto R, Sasaki H, Mitsuzuka K, Inokuchi J, Matsumura M, Yokomizo A, Kinoshita H, Hara I, Kawamura N, Hashimoto K, Inoue M, Teishima J, Kanno H, Fukuhara H, Maruyama S, Sakamoto S, Saito T, Kakehi Y, Sugimoto M: Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS- JAPAN study. Jpn J Clin Oncol. 2022 Jun; hyac092. [5y-IF: 2.864]

2022-45.

Tozawa A, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Harada M, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, Shinohara N, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Suzuki N, Osuga Y: Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2. Int J Clin Oncol. 2022 Feb; 27 (2): 281-300. [5y-IF: 3.467]

2022-46.

Ueda Y, Okamoto T, Sato Y, Hayashi A, Takahashi T, Kamada K, Honda S, Hotta K: Kidney transplantation after peritoneal dialysis-associated peritonitis and abdominal abscesses caused by Mycobacterium massiliense: lesson for the clinical nephrologist. J Nephrol. 2022 Sep; 35 (7): 1907-1910. [5y-IF: 4.206]

2022-47.

Uemura H, Tomita Y, Nonomura N, Yoshizaki K, Nakao T, Shinohara N: Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance. Int J Clin Oncol. 2022 Jun; 27 (6): 1061-1067. [5y-IF: 3.467]

2022-48.

Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, Shinohara N, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Sakamoto N: Incidence of post-transplant hepatitis B virus reactivation with the use of kidneys from donorswith resolved hepatitis B virus infection. J Viral Hepat. 2022 Aug; doi:10.1111/jvh.13740. [5y-IF: 3.430]

2022-49.

Yamada S, Abe T, Sazawa A, Katano H, Suzuki H, Takeuchi I, Ishizaki J, Minami K, Morita K, Tsuchiya K, Takada N, Maru S, Ishikawa S, Sato S, Kawazu T, Yamashita T, Ono T, Mochizuki T, Akino T, Sasaki Y, Shinno Y, Furumido J, Miyata H, Kikuchi H, Matsumoto R, Osawa T, Shinohara N: Comparative study of postoperative complications after radical cystectomy during the past two decades in Japan: Radical cystectomy remains associated with significant postoperative morbidities. Urol Oncol. 2022 Jan; 40 (1): 11.e17-11.e25. [5y-IF: 3.099]

2022-50.

Yamagata Y, Abe T, IwaharaN, Takada K, Hida Y, Takakuwa E, Kikuchi H, Matsumoto R, Osawa T, Shinohara N: Metastatic neuroendocrine carcinoma of right adrenal glandsuccessfully treated with laparoscopic adrenalectomy aftermultimodal therapy. IJU case reports. 2022 July; doi: https://doi.org/10.1002/iju5.12511. [5y-IF: N/A]

2022-51.

Yamamoto S, Noguchi H, Takeda A, Arakaki R, Uchishiba M, Imaizumi J, Minato S, Kamada S, Kagawa T, Yoshida A, Kawakita T, Yamamoto Y, Yoshida K, Kon M, Shinohara N, Iwasa T: Changes in Endogenous Oxytocin Levels and the Effects of Exogenous Oxytocin Administration on Body Weight Changes and Food Intake in Polycystic Ovary Syndrome Model Rats. Int J Mol Sci. 2022 Jul; 23 (15): 8207. [5y-IF: 6.628]

ページの先頭へ戻る